{"id":"https://openalex.org/W2480979408","doi":"https://doi.org/10.1158/1538-7445.am2016-4863","title":"Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors","display_name":"Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors","alternate_titles":[],"publication_year":2016,"publication_date":"2016-07-15","ids":{"openalex":"https://openalex.org/W2480979408","doi":"https://doi.org/10.1158/1538-7445.am2016-4863","mag":"2480979408"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2016-4863","doi":"https://doi.org/10.1158/1538-7445.am2016-4863","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-4863","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2480979408"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035122235","display_name":"Joseph R. Tumang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Tumang","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042409986","display_name":"Bruno Gomes","orcid":"https://orcid.org/0000-0002-5569-0526","observed_orcids":["https://orcid.org/0000-0002-5569-0526"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruno Gomes","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063500857","display_name":"Martin J. Wythes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Wythes","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071595199","display_name":"Stefano Crosignani","orcid":"https://orcid.org/0009-0009-6316-3265","observed_orcids":["https://orcid.org/0009-0009-6316-3265"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefano Crosignani","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037624846","display_name":"Patrick Bingham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Bingham","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064871353","display_name":"Pauline Bottemanne","orcid":"https://orcid.org/0000-0003-0414-4127","observed_orcids":["https://orcid.org/0000-0003-0414-4127"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pauline Bottemanne","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070048972","display_name":"H\u00e9l\u00e8ne Cannelle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H\u00e9l\u00e8ne Cannelle","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032888152","display_name":"Sandra Cauwenberghs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra Cauwenberghs","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031291457","display_name":"Jenny Chaplin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Chaplin","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047357717","display_name":"Deepak Dalvie","orcid":"https://orcid.org/0000-0001-6196-5314","observed_orcids":["https://orcid.org/0000-0001-6196-5314"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deepak Dalvie","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091214474","display_name":"Sofie Denies","orcid":"https://orcid.org/0009-0008-0019-8025","observed_orcids":["https://orcid.org/0009-0008-0019-8025"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sofie Denies","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012886038","display_name":"Coraline De Maeseneire","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Coraline De Maeseneire","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025739897","display_name":"Peter Folger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Folger","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082863126","display_name":"Kim Frederix","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kim Frederix","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103219249","display_name":"Jie Guo","orcid":"https://orcid.org/0000-0003-3605-9891","observed_orcids":["https://orcid.org/0000-0003-3605-9891"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jie Guo","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103498404","display_name":"James S. Hardwick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Hardwick","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005556508","display_name":"Ken Hook","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken Hook","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043173903","display_name":"Katti Jessen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katti Jessen","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035876998","display_name":"Erick K. Kindt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erick Kindt","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024323910","display_name":"Marie-Claire Letellier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marie-Claire Letellier","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112195210","display_name":"Kai\u2010Hsin Liao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kai-Hsin Liao","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020133148","display_name":"Wenlin Li","orcid":"https://orcid.org/0000-0002-0842-222X","observed_orcids":["https://orcid.org/0000-0002-0842-222X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenlin Li","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071409456","display_name":"Karen A. Maegley","orcid":"https://orcid.org/0000-0002-5467-3177","observed_orcids":["https://orcid.org/0000-0002-5467-3177"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Maegley","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084946547","display_name":"Reece G. Marillier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reece Marillier","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058150315","display_name":"Nichol L. G. Miller","orcid":"https://orcid.org/0000-0002-4805-3385","observed_orcids":["https://orcid.org/0000-0002-4805-3385"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nichol Miller","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016038666","display_name":"Brion William Murray","orcid":"https://orcid.org/0000-0003-1591-2566","observed_orcids":["https://orcid.org/0000-0003-1591-2566"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brion Murray","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087148709","display_name":"Romain Pirson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Romain Pirson","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034833034","display_name":"Julie Preillon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julie Preillon","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112211134","display_name":"Virginie Rabolli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Virginie Rabolli","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022553469","display_name":"CHAD A. RAY","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chad Ray","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110463278","display_name":"Stephanie A. Scales","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Scales","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063337220","display_name":"Jay Srirangam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Srirangam","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073976363","display_name":"Jim Solowiej","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jim Solowiej","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013106114","display_name":"Nicole Streiner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Streiner","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075323544","display_name":"Vince R. Torti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vince Torti","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000804175","display_name":"Konstantinos E. Tsaparikos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Konstantinos Tsaparikos","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103510991","display_name":"Paolo Vicini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paolo Vicini","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002197682","display_name":"Gr\u00e9gory Driessens","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory Driessens","raw_affiliation_strings":["2iTEOS Therapeutics, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2iTEOS Therapeutics, Belgium","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Manfred Kraus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manfred Kraus","raw_affiliation_strings":["1Pfizer, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer, San Diego, CA;","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"76","issue":"14_Supplement","first_page":"4863","last_page":"4863"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.009499999694526196,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/indoleamine-2-3-dioxygenase","display_name":"indoleamine 2,3-dioxygenase","score":0.9290000200271606},{"id":"https://openalex.org/keywords/tryptophan-catabolism","display_name":"tryptophan catabolism","score":0.9169999957084656},{"id":"https://openalex.org/keywords/kynurenine","display_name":"kynurenine","score":0.9750000238418579},{"id":"https://openalex.org/keywords/tumor-immunosuppression","display_name":"tumor immunosuppression","score":0.8399999737739563},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.847000002861023},{"id":"https://openalex.org/keywords/t-cell-anergy","display_name":"T cell anergy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.8529999852180481},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8539999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8519999980926514},{"id":"https://openalex.org/keywords/syngeneic-mouse-model","display_name":"syngeneic mouse model","score":0.7570000290870667}],"concepts":[{"id":"https://openalex.org/C2777503454","wikidata":"https://www.wikidata.org/wiki/Q415768","display_name":"Kynurenine","level":4,"score":0.6888409852981567},{"id":"https://openalex.org/C83478079","wikidata":"https://www.wikidata.org/wiki/Q908221","display_name":"Indoleamine 2,3-dioxygenase","level":4,"score":0.6721221804618835},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5880230069160461},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5673519372940063},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5636395215988159},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5565295219421387},{"id":"https://openalex.org/C2779727006","wikidata":"https://www.wikidata.org/wiki/Q426188","display_name":"FOXP3","level":3,"score":0.5149115324020386},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.49918627738952637},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.46853676438331604},{"id":"https://openalex.org/C2777702733","wikidata":"https://www.wikidata.org/wiki/Q1356761","display_name":"Immune tolerance","level":3,"score":0.46072012186050415},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4572891294956207},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4019603729248047},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.39493364095687866},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3698403835296631},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3564232587814331},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.31239643692970276},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.221853107213974},{"id":"https://openalex.org/C2776706248","wikidata":"https://www.wikidata.org/wiki/Q181003","display_name":"Tryptophan","level":3,"score":0.15489214658737183},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1172163188457489},{"id":"https://openalex.org/C515207424","wikidata":"https://www.wikidata.org/wiki/Q8066","display_name":"Amino acid","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2016-4863","doi":"https://doi.org/10.1158/1538-7445.am2016-4863","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-4863","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891925600","https://openalex.org/W1537518951","https://openalex.org/W6987000001","https://openalex.org/W2741787889","https://openalex.org/W2885978192","https://openalex.org/W2767640831","https://openalex.org/W2134427503","https://openalex.org/W2485876986","https://openalex.org/W2612223042","https://openalex.org/W2885199971"],"abstract_inverted_index":{"Abstract":[0],"Tumors":[1],"use":[2],"tryptophan-catabolizing":[3],"enzymes":[4],"such":[5,41],"as":[6,42,171],"Indoleamine":[7],"2,3-dioxygenase-1":[8],"(IDO-1)":[9],"to":[10,24,29,38,63],"induce":[11],"an":[12,90],"immunosuppressive":[13,86],"microenvironment.":[14],"IDO-1":[15,33,60,103,112,262],"expression":[16],"is":[17,34,78,106],"upregulated":[18],"in":[19,36,94,119,128,136,141,143,175,267,270],"many":[20],"cancers":[21],"and":[22,44,53,67,88,99,132],"described":[23],"be":[25],"a":[26,79,101,107,157,172,259],"resistance":[27],"mechanism":[28],"immune":[30,46,146,273],"checkpoint":[31,147,274],"therapies.":[32],"induced":[35],"response":[37],"inflammatory":[39],"stimuli":[40],"IFN-\u00e3":[43],"promotes":[45],"tolerance":[47],"through":[48,71],"the":[49,82,166,280,285],"catabolism":[50],"of":[51,55,73,84,160,169,279,284],"tryptophan":[52,56],"accumulation":[54],"catabolites":[57],"including":[58,156],"kynurenine.":[59],"activity":[61],"leads":[62],"effector":[64],"T-cell":[65,117],"anergy":[66,118],"enhanced":[68],"Treg":[69],"function":[70],"upregulation":[72],"FoxP3.":[74],"As":[75],"such,":[76],"IDO1":[77],"nexus":[80],"for":[81,288],"induction":[83],"key":[85],"mechanisms":[87],"represents":[89],"important":[91],"immunotherapeutic":[92],"target":[93],"oncology.":[95],"We":[96],"have":[97],"identified":[98],"characterized":[100],"new":[102],"inhibitor.":[104,113],"PF-06840003":[105,114,123,170],"highly":[108,260],"selective":[109,261],"orally":[110],"bioavailable":[111],"reversed":[115],"IDO-1-induced":[116],"vitro.":[120],"In":[121],"vivo,":[122],"reduced":[124],"intratumoral":[125],"kynurenine":[126],"levels":[127],"mice":[129],"by":[130],">80%":[131],"inhibited":[133],"tumor":[134],"growth":[135],"multiple":[137],"preclinical":[138],"syngeneic":[139],"models":[140],"mice,":[142],"combination":[144,271],"with":[145,272],"inhibitors.":[148,275],"PF-0684003":[149],"has":[150],"favorable":[151],"predicted":[152,158],"human":[153],"pharmacokinetic":[154],"properties,":[155],"t1/2":[159],"16-19":[161],"hours.":[162],"These":[163],"studies":[164],"highlight":[165],"strong":[167],"potential":[168],"clinical":[173],"candidate":[174],"Immuno-Oncology.":[176],"Citation":[177],"Format:":[178],"Joseph":[179],"Tumang,":[180],"Bruno":[181],"Gomes,":[182],"Martin":[183],"Wythes,":[184],"Stefano":[185],"Crosignani,":[186],"Patrick":[187],"Bingham,":[188],"Pauline":[189],"Bottemanne,":[190],"H\u00e9l\u00e8ne":[191],"Cannelle,":[192],"Sandra":[193],"Cauwenberghs,":[194],"Jenny":[195],"Chaplin,":[196],"Deepak":[197],"Dalvie,":[198],"Sofie":[199],"Denies,":[200],"Coraline":[201],"De":[202],"Maeseneire,":[203],"Peter":[204],"Folger,":[205],"Kim":[206],"Frederix,":[207],"Jie":[208],"Guo,":[209],"James":[210],"Hardwick,":[211],"Ken":[212],"Hook,":[213],"Katti":[214],"Jessen,":[215],"Erick":[216],"Kindt,":[217],"Marie-Claire":[218],"Letellier,":[219],"Kai-Hsin":[220],"Liao,":[221],"Wenlin":[222],"Li,":[223],"Karen":[224],"Maegley,":[225],"Reece":[226],"Marillier,":[227],"Nichol":[228],"Miller,":[229],"Brion":[230],"Murray,":[231],"Romain":[232],"Pirson,":[233],"Julie":[234],"Preillon,":[235],"Virginie":[236],"Rabolli,":[237],"Chad":[238],"Ray,":[239],"Stephanie":[240],"Scales,":[241],"Jay":[242],"Srirangam,":[243],"Jim":[244],"Solowiej,":[245],"Nicole":[246],"Streiner,":[247],"Vince":[248],"Torti,":[249],"Konstantinos":[250],"Tsaparikos,":[251],"Paolo":[252],"Vicini,":[253],"Gregory":[254],"Driessens,":[255],"Manfred":[256],"Kraus.":[257],"PF-06840003:":[258],"inhibitor":[263],"that":[264],"shows":[265],"good":[266],"vivo":[268],"efficacy":[269],"[abstract].":[276],"In:":[277],"Proceedings":[278],"107th":[281],"Annual":[282],"Meeting":[283],"American":[286],"Association":[287],"Cancer":[289,300],"Research;":[290],"2016":[291],"Apr":[292],"16-20;":[293],"New":[294],"Orleans,":[295],"LA.":[296],"Philadelphia":[297],"(PA):":[298],"AACR;":[299],"Res":[301],"2016;76(14":[302],"Suppl):Abstract":[303],"nr":[304],"4863.":[305]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2480979408","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":4}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2016-08-23T00:00:00"}
